BioSpace News Archive

Christopher Chen, CEO of ChenMed, a leading provider of primary care to underserved seniors, will be featured in a “Meet the Primary Care Market Movers” session at the 2022 National Primary Care Transformation Summit.

Argonaut Manufacturing Services, a contract manufacturing organization serving the biopharma, life sciences, and molecular diagnostics industries, announced the launch of LyoDots,*TM the world’s smallest lyophilized reagents.

Immuron Limited announced that the US Naval Medical Research Center has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ETEC.

Centene Corporation announced its financial results for the second quarter ended June 30, 2022.

GenScript USA Inc., the world’s leading life-science research tools and services provider, announced its second annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research.

Alzheon, Inc. announced that it will be presenting at the 2022 Alzheimer’s Association International Conference to be held on July 31 – August 4, 2022 in San Diego, California, USA. Alzheon Chief Medical Officer, Susan Abushakra, MD, will give a podium presentation at the AAIC conference on Sunday, July 31, 2022, at 8 a.m. PT or 11 a.m. ET.

RepliCel Life Sciences Inc. announced it has now received and analyzed all data and images from independent laboratory testing of the DermaPreciseTM injector prototype and consumables evaluating the injection systems’ various depths and doses in donated human skin tissue.

RetinalGenix™ Technologies, Inc., announced the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies, Inc. Board of Directors.

Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate updates for the second quarter of 2022.

MediciNova, Inc. announced the initiation of a Phase 2 clinical trial to evaluate MN-001 for the treatment of patients with non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia.